CLINICAL_TRIALS ClinicalTrials.gov record update

A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05007106
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:27.222591+00:00
Published At: 2025-08-14T00:00:00+00:00
Record Updated At: 2025-08-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-14"
protocolSection.identificationModule.nctId: "NCT05007106"
protocolSection.identificationModule.officialTitle: "A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.